Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
The Drug Information Association’s (DIA’s) 21st Annual EuroMeeting will feature more than 125
The Drug Information Association’s (DIA’s) 21st Annual EuroMeeting will feature more than 125
GlaxoSmithKline announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria(R) (albiglutide) in men …
GlaxoSmithKline announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria(R) (albiglutide) in men …
Nektar Therapeutics (Nasdaq: NKTR) announced that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Phase 1 study will assess the safety, …
Nektar Therapeutics (Nasdaq: NKTR) announced that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Phase 1 study will assess the safety, …
In a review of influenza vaccine studies published in the British Medical Journal Tom Jefferson, M.D., Ph.D. (Cochrane Field, Rome, Italy) and colleagues found that published influenza vaccine studies sponsored by industry are treated …
In a review of influenza vaccine studies published in the British Medical Journal Tom Jefferson, M.D., Ph.D. (Cochrane Field, Rome, Italy) and colleagues found that published influenza vaccine studies sponsored by industry are treated …
Roche Products Limited has been reinstated to membership of the Association of the British Pharmaceutical Industry (ABPI) following the company’s suspension from 14 July 2008. The ABPI Board of Management decided that Roche …
Roche Products Limited has been reinstated to membership of the Association of the British Pharmaceutical Industry (ABPI) following the company’s suspension from 14 July 2008. The ABPI Board of Management decided that Roche …
Scientists announced the publication of a landmark peer-reviewed paper in the February issue of the Bentham Open Stem Cell Journal which outlines the long term results of the world’s first clinical trial using autologous neural …
Scientists announced the publication of a landmark peer-reviewed paper in the February issue of the Bentham Open Stem Cell Journal which outlines the long term results of the world’s first clinical trial using autologous neural …
In a new study, duloxetine hydrochloride (Cymbalta®), administered at 60 mg to 120 mg taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the …
In a new study, duloxetine hydrochloride (Cymbalta®), administered at 60 mg to 120 mg taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the …
Sandoz has received final approval for its third biosimilar, filgrastim, paving the way for this important oncology medicine to be made available to patients across the European Union. Filgrastim is indicated …
Sandoz has received final approval for its third biosimilar, filgrastim, paving the way for this important oncology medicine to be made available to patients across the European Union. Filgrastim is indicated …
European food companies already use nanotechnology in consumer products, but few volunteer the information to consumers, said Dutch food scientist Frans Kampers. He is among the panelists gathered in Chicago for the …
Proposed legislation aims to take a controversial option away from brand-name drug makers in their fight against generics. Last week, senators Herb Kohl (D-WI) …
SK&A, a leading provider of healthcare information solutions and research, today announced the latest results of its ongoing survey of U.S. medical practices to …
Researchers from Nano-Science Center, University of Copenhagen and National Centre for Scientific Research, France have developed a general method to study membrane proteins. This method can be used to screen several thousand proteins, and it …
| NASDAQ | 2235.41 | ||
| S&P 500 | 1104.84 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||